Vertex Pharmaceuticals (NASDAQ:VRTX) PT Set at $439.00 by Morgan Stanley

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) has been assigned a $439.00 target price by equities research analysts at Morgan Stanley in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage currently has an “equal weight” rating on the pharmaceutical company’s stock. Morgan Stanley’s price target would indicate a potential upside of 13.83% […]

Leave a Reply

Your email address will not be published.

Previous post Royal Bank Of Canada Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
Next post KBC Group (KBCSY) to Release Earnings on Thursday